327 related articles for article (PubMed ID: 37867526)
1. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
2. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
3. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
4. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
6. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
7. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
8. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
9. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Menendez JA; Alarcón T; Joven J
Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
[TBL] [Abstract][Full Text] [Related]
10. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
12. SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.
Armstrong N; Storey CM; Noll SE; Margulis K; Soe MH; Xu H; Yeh B; Fishbein L; Kebebew E; Howitt BE; Zare RN; Sage J; Annes JP
Cell Rep; 2022 Mar; 38(9):110453. PubMed ID: 35235785
[TBL] [Abstract][Full Text] [Related]
13. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
14. New insights on the pathogenesis of paraganglioma and pheochromocytoma.
Kantorovich V; Pacak K
F1000Res; 2018; 7():. PubMed ID: 30345003
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
Remacha L; Pirman D; Mahoney CE; Coloma J; Calsina B; Currás-Freixes M; Letón R; Torres-Pérez R; Richter S; Pita G; Herráez B; Cianchetta G; Honrado E; Maestre L; Urioste M; Aller J; García-Uriarte Ó; Gálvez MÁ; Luque RM; Lahera M; Moreno-Rengel C; Eisenhofer G; Montero-Conde C; Rodríguez-Antona C; Llorca Ó; Smolen GA; Robledo M; Cascón A
Am J Hum Genet; 2019 Apr; 104(4):651-664. PubMed ID: 30929736
[TBL] [Abstract][Full Text] [Related]
16. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
17. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
[TBL] [Abstract][Full Text] [Related]
18. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract][Full Text] [Related]
19. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
Jochmanová I; Yang C; Zhuang Z; Pacak K
J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
